Our study found that PTGDS inhibition could sensitize DLBCL cells to adriamycin and bendamustine through promoting DNA damage, supporting the potential of AT56 in combination chemotherapy for DLBCL. Here, PTGDS is linked to diffuse large B-cell lymphoma.